Business
Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes
- Neil Leatherbury Appointed Senior Vice President, Head of CMC – - Derek Jantz, Ph.D., to Assume Advisory Position of Co-Founder and Chief Science Advisor –
About this update from Precision Biosciences, Inc.
[{"type":"text","content":"\n- Neil Leatherbury Appointed Senior Vice President, Head of CMC –\n\n- Derek Jantz, Ph.D., to Assume Advisory Position of Co-Founder and Chief Science Advisor –\n\n- Jeff Smith, Ph.D., Co-Founder and Chief Research Officer Continues to Lead Research Strategy and Day-to-Day Execution of the Research Function –\n\n DURHAM, N.C.--(BUSINESS WIRE)--\nPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and organizational changes within the Company’s Senior Leadership Team (SLT).\n\nThe company announced the promotion of Neil Leatherbury to Senior Vice President, Head of Chemistry, Manufacturing and Controls (CMC) reporting directly to Michael Amoroso, President and Chief Executive Officer. Mr. Leatherbury leads Precision’s teams responsible for gene delivery, analytical development, process development, manufacturing, supply chain and manufacturing science and technology.\n\n“I’m pleased to announce the promotion of Neil to lead our CMC teams as member of the SLT. He has done an excellent job leading his team through a successful allogeneic CAR T manufacturing optimization process that improved our cell manufacturing platform resulting in enhanced CAR T attributes that are associated with efficacy and safety,” said Michael Amoroso. “This work was instrumental in achieving favorable Type C feedback from the FDA on the company’s CMC processes and analytical methods in support of late-stage development for azercabtagene zapreleucel (azer-cel), our lead clinical stage allogeneic CAR T cell candidate. We look forward to building on this success with our CAR T programs in 2023.”\n\nIn addition, the company announced that Derek Jantz, Ph.D., Co-Founder and Chief Scientific Officer, has announced his intentions to gradually step away from his current day-to-day responsibilities at the Company to pursue other personal and professional interests while continuing to support the Company’s external relationships, including existing and potential business development partners. He will assume an advisory role as Co-Founder, Chief Science Advisor. In this capacity, Dr. Jantz is expected to provide ongoing platform advice and support to the Company’s executive team, as well as the Board of Directors' Science ...